(Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

The new drug, amycretin, similar to the company's blockbuster weight-loss and diabetes drugs Wegovy and Ozempic ... "Although ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Scientists are tackling society's growing obesity problem from all kinds of angles – and new research picks out a particular ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise ...

But this same mechanism may increase the risk of rare ... similar warnings as the popularity of Ozempic and other weight-loss drugs has risen. In the U.S. alone, at least 12% of adults have ...